PPARγ is indeed the best-characterized target of the insulin-sensitizers of the thiazolidinedione family used in the treatment of type 2 diabetes, and its use as a therapeutic anti-cancer target is also a matter of debate. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.